Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-12-28
Based on 1222 first isolates · PHC-S · Cystitis (lower UTI) · 2024-12-29 → 2025-12-28
Health centre South
Per-organism detail: PHC-S urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 82 % (79 %–84 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (8 %), Pseudomonas aeruginosa (6 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
82 %
80 %
n = 76
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
82 %
84 %
n = 76
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
78 %
78 %
n = 76
ciprofloxacin CIP
trend · Escherichia coli
76 %
78 %
n = 76
ceftriaxone CRO
trend · Escherichia coli
74 %
70 %
n = 76
mecillinam MEC
trend · Escherichia coli lower UTI only
74 %
70 %
n = 76
trimethoprim TMP
trend · Escherichia coli lower UTI only
70 %
68 %
n = 76
69 %
64 %
n = 76
51 %
54 %
n = 76
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
15 %
16 %
n = 76
5 %
8 %
n = 76
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
3 %
n = 76

Most likely organisms for this profile

Escherichia coli
49 %
Klebsiella pneumoniae
13 %
Enterococcus faecalis
11 %
Proteus mirabilis
8 %
Pseudomonas aeruginosa
6 %
Staphylococcus aureus
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.